{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T17:15:03Z","timestamp":1784049303406,"version":"3.55.0"},"reference-count":62,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,1,3]],"date-time":"2024-01-03T00:00:00Z","timestamp":1704240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,1,3]],"date-time":"2024-01-03T00:00:00Z","timestamp":1704240000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004082","name":"Korean Foundation for Cancer Research","doi-asserted-by":"publisher","award":["CB-2017-A-2"],"award-info":[{"award-number":["CB-2017-A-2"]}],"id":[{"id":"10.13039\/501100004082","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004082","name":"Korean Foundation for Cancer Research","doi-asserted-by":"publisher","award":["CB-2017-A-2"],"award-info":[{"award-number":["CB-2017-A-2"]}],"id":[{"id":"10.13039\/501100004082","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004082","name":"Korean Foundation for Cancer Research","doi-asserted-by":"publisher","award":["CB-2017-A-2"],"award-info":[{"award-number":["CB-2017-A-2"]}],"id":[{"id":"10.13039\/501100004082","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004082","name":"Korean Foundation for Cancer Research","doi-asserted-by":"publisher","award":["CB-2017-A-2"],"award-info":[{"award-number":["CB-2017-A-2"]}],"id":[{"id":"10.13039\/501100004082","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004082","name":"Korean Foundation for Cancer Research","doi-asserted-by":"publisher","award":["CB-2017-A-2"],"award-info":[{"award-number":["CB-2017-A-2"]}],"id":[{"id":"10.13039\/501100004082","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004082","name":"Korean Foundation for Cancer Research","doi-asserted-by":"publisher","award":["CB-2017-A-2"],"award-info":[{"award-number":["CB-2017-A-2"]}],"id":[{"id":"10.13039\/501100004082","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003670","name":"National Evidence-based Healthcare Collaborating Agency","doi-asserted-by":"publisher","award":["NA21-003"],"award-info":[{"award-number":["NA21-003"]}],"id":[{"id":"10.13039\/501100003670","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003670","name":"National Evidence-based Healthcare Collaborating Agency","doi-asserted-by":"publisher","award":["NA21-003"],"award-info":[{"award-number":["NA21-003"]}],"id":[{"id":"10.13039\/501100003670","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003670","name":"National Evidence-based Healthcare Collaborating Agency","doi-asserted-by":"publisher","award":["NA21-003"],"award-info":[{"award-number":["NA21-003"]}],"id":[{"id":"10.13039\/501100003670","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003670","name":"National Evidence-based Healthcare Collaborating Agency","doi-asserted-by":"publisher","award":["NA21-003"],"award-info":[{"award-number":["NA21-003"]}],"id":[{"id":"10.13039\/501100003670","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003670","name":"National Evidence-based Healthcare Collaborating Agency","doi-asserted-by":"publisher","award":["NA21-003"],"award-info":[{"award-number":["NA21-003"]}],"id":[{"id":"10.13039\/501100003670","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>We aimed to summarize the cancer risk among patients with indication of group I pharmaceuticals as stated in monographs presented by the International Agency for Research on Cancer working groups. Following the PRISMA guidelines, a comprehensive literature search was conducted using the PubMed database. Pharmaceuticals with few studies on cancer risk were identified in systematic reviews; those with two or more studies were subjected to meta-analysis. For the meta-analysis, a random-effects model was used to calculate the summary relative risks (SRRs) and 95% confidence intervals (95% CIs). Heterogeneity across studies was presented using the Higgins I square value from Cochran\u2019s Q test. Among the 12 group I pharmaceuticals selected, three involved a single study [etoposide, thiotepa, and mustargen\u2009+\u2009oncovin\u2009+\u2009procarbazine\u2009+\u2009prednisone (MOPP)], seven had two or more studies [busulfan, cyclosporine, azathioprine, cyclophosphamide, methoxsalen\u2009+\u2009ultraviolet (UV) radiation therapy, melphalan, and chlorambucil], and two did not have any studies [etoposide\u2009+\u2009bleomycin\u2009+\u2009cisplatin and treosulfan]. Cyclosporine and azathioprine reported increased skin cancer risk (SRR\u2009=\u20091.32, 95% CI 1.07\u20131.62; SRR\u2009=\u20091.56, 95% CI 1.25\u20131.93) compared to non-use. Cyclophosphamide increased bladder and hematologic cancer risk (SRR\u2009=\u20092.87, 95% CI 1.32\u20136.23; SRR\u2009=\u20092.43, 95% CI 1.65\u20133.58). Busulfan increased hematologic cancer risk (SRR\u2009=\u20096.71, 95% CI 2.49\u201318.08); melphalan was associated with hematologic cancer (SRR\u2009=\u20094.43, 95% CI 1.30\u201315.15). In the systematic review, methoxsalen\u2009+\u2009UV and MOPP were\u00a0associated with an increased risk of skin and lung cancer, respectively. Our results can enhance persistent surveillance of group I pharmaceutical use, establish novel clinical strategies for patients with indications, and provide evidence for re-categorizing current group I pharmaceuticals into other groups.<\/jats:p>","DOI":"10.1038\/s41598-023-50602-6","type":"journal-article","created":{"date-parts":[[2024,1,3]],"date-time":"2024-01-03T18:01:59Z","timestamp":1704304919000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Group I pharmaceuticals of IARC and associated cancer risks: systematic review and meta-analysis"],"prefix":"10.1038","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8305-0246","authenticated-orcid":false,"given":"Woojin","family":"Lim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6668-3065","authenticated-orcid":false,"given":"Sungji","family":"Moon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6155-9906","authenticated-orcid":false,"given":"Na Rae","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5365-437X","authenticated-orcid":false,"given":"Ho Gyun","family":"Shin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5488-5068","authenticated-orcid":false,"given":"Su-Yeon","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1141-878X","authenticated-orcid":false,"given":"Jung Eun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3568-4484","authenticated-orcid":false,"given":"Inah","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7788-2887","authenticated-orcid":false,"given":"Kwang-Pil","family":"Ko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5002-9707","authenticated-orcid":false,"given":"Sue K.","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,1,3]]},"reference":[{"key":"50602_CR1","unstructured":"IARC Monogr Eval Carcinog Risk Chem Man. IARC monographs on the evaluation of the carcinogenic risk of chemicals to man: Some aziridines, N-, S- & O-mustards and selenium 1\u2013268 (1975)."},{"key":"50602_CR2","unstructured":"IARC Monogr Eval Carcinog Risk Chem Hum. Some pharmaceutical drugs 1\u2013337 (1980)."},{"key":"50602_CR3","unstructured":"IARC Monogr Eval Carcinog Risk Chem Hum. Some antineoplastic and immunosuppressive agents 1\u2013411 (1981)."},{"key":"50602_CR4","unstructured":"IARC Monogr Eval Carcinog Risks Hum. Pharmaceuticals. Volume 100 A. A review of human carcinogens 1\u2013401 (2012)."},{"key":"50602_CR5","unstructured":"Some Drugs and Herbal Products. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans 1\u2013419 (2016)."},{"issue":"11","key":"50602_CR6","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1016\/S1470-2045(20)30611-2","volume":"21","author":"S Warnakulasuriya","year":"2020","unstructured":"Warnakulasuriya, S. et al. Carcinogenicity of opium consumption. Lancet Oncol. 21(11), 1407\u20131408 (2020).","journal-title":"Lancet Oncol."},{"key":"50602_CR7","unstructured":"IARC Monogr Eval Carcinog Risks Hum Suppl. Overall evaluations of carcinogenicity: An updating of IARC Monographs volumes 1 to 42 1\u2013440 (1987)."},{"issue":"5724","key":"50602_CR8","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1136\/bmj.3.5724.684","volume":"3","author":"B Laursen","year":"1970","unstructured":"Laursen, B. Cancer of the bladder in patients treated with chlornaphazine. Br. Med. J. 3(5724), 684\u2013685 (1970).","journal-title":"Br. Med. J."},{"issue":"4","key":"50602_CR9","doi-asserted-by":"publisher","first-page":"420","DOI":"10.5195\/jmla.2018.345","volume":"106","author":"MB Eriksen","year":"2018","unstructured":"Eriksen, M. B. & Frandsen, T. F. The impact of patient, intervention, comparison, outcome (PICO) as a search strategy tool on literature search quality: A systematic review. J. Med. Libr. Assoc. 106(4), 420\u2013431 (2018).","journal-title":"J. Med. Libr. Assoc."},{"key":"50602_CR10","unstructured":"IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Ciclosporin 77\u2013114 (1990)."},{"key":"50602_CR11","unstructured":"IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Thiotepa 123\u2013141 (1990)."},{"issue":"5","key":"50602_CR12","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1016\/j.cgh.2014.05.015","volume":"13","author":"DS Kotlyar","year":"2015","unstructured":"Kotlyar, D. S. et al. Risk of lymphoma in patients with inflammatory bowel disease treated with azathioprine and 6-mercaptopurine: A meta-analysis. Clin. Gastroenterol. Hepatol. 13(5), 847\u2013858 (2015).","journal-title":"Clin. Gastroenterol. Hepatol."},{"issue":"5","key":"50602_CR13","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.3390\/jcm9051449","volume":"9","author":"BL Freedman","year":"2020","unstructured":"Freedman, B. L. et al. Treatment of overlap syndromes in autoimmune liver disease: A systematic review and meta-analysis. J. Clin. Med. 9(5), 1449 (2020).","journal-title":"J. Clin. Med."},{"issue":"5","key":"50602_CR14","doi-asserted-by":"publisher","first-page":"301","DOI":"10.3961\/jpmph.21.160","volume":"54","author":"HG Byun","year":"2021","unstructured":"Byun, H. G., Lee, N. & Hwang, S.-S. A systematic review of spatial and spatio-temporal analyses in public health research in Korea. J. Prev. Med. Public Health 54(5), 301\u2013308 (2021).","journal-title":"J. Prev. Med. Public Health"},{"issue":"2","key":"50602_CR15","doi-asserted-by":"publisher","first-page":"92","DOI":"10.3163\/1536-5050.101.2.004","volume":"101","author":"T Bekhuis","year":"2013","unstructured":"Bekhuis, T., Demner-Fushman, D. & Crowley, R. S. Comparative effectiveness research designs: An analysis of terms and coverage in Medical Subject Headings (MeSH) and Emtree. J. Med. Libr. Assoc. 101(2), 92\u2013100 (2013).","journal-title":"J. Med. Libr. Assoc."},{"key":"50602_CR16","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page, M. J. et al. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. Bmj 372, n71 (2021).","journal-title":"Bmj"},{"issue":"8","key":"50602_CR17","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1136\/gut.2004.049460","volume":"54","author":"A Kandiel","year":"2005","unstructured":"Kandiel, A. et al. Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine. Gut 54(8), 1121\u20131125 (2005).","journal-title":"Gut"},{"key":"50602_CR18","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s12874-015-0034-x","volume":"15","author":"E Kulinskaya","year":"2015","unstructured":"Kulinskaya, E. & Dollinger, M. B. An accurate test for homogeneity of odds ratios based on Cochran\u2019s Q-statistic. BMC Med. Res. Methodol. 15, 49 (2015).","journal-title":"BMC Med. Res. Methodol."},{"key":"50602_CR19","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/978-3-319-21416-0_1","volume-title":"Meta-Analysis with R","author":"G Schwarzer","year":"2015","unstructured":"Schwarzer, G., Carpenter, J. R. & R\u00fccker, G. An introduction to meta-analysis in R. In Meta-Analysis with R 3\u201317 (Springer, 2015)."},{"issue":"9","key":"50602_CR20","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1016\/j.mayocp.2018.04.025","volume":"93","author":"M Bhat","year":"2018","unstructured":"Bhat, M. et al. Immunosuppression, race, and donor-related risk factors affect de novo cancer incidence across solid organ transplant recipients. Mayo Clin. Proc. 93(9), 1236\u20131246 (2018).","journal-title":"Mayo Clin. Proc."},{"issue":"11","key":"50602_CR21","doi-asserted-by":"publisher","first-page":"2741","DOI":"10.1002\/ijc.31735","volume":"143","author":"EK Cahoon","year":"2018","unstructured":"Cahoon, E. K. et al. Risk of Kaposi sarcoma after solid organ transplantation in the United States. Int. J. Cancer 143(11), 2741\u20132748 (2018).","journal-title":"Int. J. Cancer"},{"issue":"2","key":"50602_CR22","doi-asserted-by":"publisher","first-page":"dju382","DOI":"10.1093\/jnci\/dju382","volume":"107","author":"CA Clarke","year":"2015","unstructured":"Clarke, C. A. et al. Risk of merkel cell carcinoma after solid organ transplantation. J. Natl. Cancer Inst. 107(2), dju382 (2015).","journal-title":"J. Natl. Cancer Inst."},{"issue":"2","key":"50602_CR23","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1111\/ajt.13596","volume":"16","author":"AE Coghill","year":"2016","unstructured":"Coghill, A. E. et al. Immunosuppressive medications and squamous cell skin carcinoma: Nested case-control study within the skin cancer after organ transplant (SCOT) cohort. Am. J. Transplant. 16(2), 565\u2013573 (2016).","journal-title":"Am. J. Transplant."},{"issue":"1","key":"50602_CR24","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1111\/ajt.14500","volume":"18","author":"B Hamandi","year":"2018","unstructured":"Hamandi, B. et al. Voriconazole and squamous cell carcinoma after lung transplantation: A multicenter study. Am. J. Transplant. 18(1), 113\u2013124 (2018).","journal-title":"Am. J. Transplant."},{"issue":"8","key":"50602_CR25","doi-asserted-by":"publisher","first-page":"2764","DOI":"10.1093\/ndt\/gfp425","volume":"25","author":"A Ingvar","year":"2010","unstructured":"Ingvar, A. et al. Immunosuppressive treatment after solid organ transplantation and risk of post-transplant cutaneous squamous cell carcinoma. Nephrol. Dial. Transplant. 25(8), 2764\u20132771 (2010).","journal-title":"Nephrol. Dial. Transplant."},{"issue":"2 Pt 1","key":"50602_CR26","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/S0190-9622(99)70185-4","volume":"40","author":"P Jensen","year":"1999","unstructured":"Jensen, P. et al. Skin cancer in kidney and heart transplant recipients and different long-term immunosuppressive therapy regimens. J. Am. Acad. Dermatol. 40(2 Pt 1), 177\u2013186 (1999).","journal-title":"J. Am. Acad. Dermatol."},{"issue":"6","key":"50602_CR27","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1111\/j.1600-6143.2004.00450.x","volume":"4","author":"BL Kasiske","year":"2004","unstructured":"Kasiske, B. L. et al. Cancer after kidney transplantation in the United States. Am. J. Transplant. 4(6), 905\u2013913 (2004).","journal-title":"Am. J. Transplant."},{"key":"50602_CR28","first-page":"w13036","volume":"140","author":"B Keller","year":"2010","unstructured":"Keller, B. et al. Skin cancers in renal transplant recipients: A description of the renal transplant cohort in Bern. Swiss Med. Wkly. 140, w13036 (2010).","journal-title":"Swiss Med. Wkly."},{"issue":"9","key":"50602_CR29","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.1093\/rheumatology\/kew214","volume":"55","author":"E Lange","year":"2016","unstructured":"Lange, E. et al. Disease-modifying anti-rheumatic drugs and non-melanoma skin cancer in inflammatory arthritis patients: A retrospective cohort study. Rheumatology 55(9), 1594\u20131600 (2016).","journal-title":"Rheumatology"},{"issue":"10","key":"50602_CR30","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1053\/jlts.2002.35551","volume":"8","author":"AB Mithoefer","year":"2002","unstructured":"Mithoefer, A. B., Supran, S. & Freeman, R. B. Risk factors associated with the development of skin cancer after liver transplantation. Liver Transplant. 8(10), 939\u2013944 (2002).","journal-title":"Liver Transplant."},{"issue":"8","key":"50602_CR31","doi-asserted-by":"publisher","first-page":"3001","DOI":"10.1016\/j.transproceed.2010.08.003","volume":"42","author":"BD Molina","year":"2010","unstructured":"Molina, B. D. et al. Incidence and risk factors for nonmelanoma skin cancer after heart transplantation. Transplant. Proc. 42(8), 3001\u20133005 (2010).","journal-title":"Transplant. Proc."},{"issue":"3","key":"50602_CR32","first-page":"471","volume":"36","author":"HW Tseng","year":"2018","unstructured":"Tseng, H. W. et al. The influence of disease-modifying anti-rheumatic drugs and corticosteroids on the association between rheumatoid arthritis and skin cancer: A nationwide retrospective case-control study in Taiwan. Clin. Exp. Rheumatol. 36(3), 471\u2013478 (2018).","journal-title":"Clin. Exp. Rheumatol."},{"issue":"6","key":"50602_CR33","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1097\/01.tp.0000203554.54242.56","volume":"81","author":"S Caillard","year":"2006","unstructured":"Caillard, S. et al. Myeloma, Hodgkin disease, and lymphoid leukemia after renal transplantation: Characteristics, risk factors and prognosis. Transplantation 81(6), 888\u2013895 (2006).","journal-title":"Transplantation"},{"issue":"3","key":"50602_CR34","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1111\/j.1600-6143.2011.03896.x","volume":"12","author":"S Caillard","year":"2012","unstructured":"Caillard, S. et al. Epidemiology of posttransplant lymphoproliferative disorders in adult kidney and kidney pancreas recipients: Report of the French registry and analysis of subgroups of lymphomas. Am. J. Transplant. 12(3), 682\u2013693 (2012).","journal-title":"Am. J. Transplant."},{"issue":"11","key":"50602_CR35","doi-asserted-by":"publisher","first-page":"2472","DOI":"10.1111\/j.1600-6143.2011.03704.x","volume":"11","author":"P Fernberg","year":"2011","unstructured":"Fernberg, P. et al. Time trends in risk and risk determinants of non-Hodgkin lymphoma in solid organ transplant recipients. Am. J. Transplant. 11(11), 2472\u20132482 (2011).","journal-title":"Am. J. Transplant."},{"issue":"4","key":"50602_CR36","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1111\/bjh.14083","volume":"174","author":"R Na","year":"2016","unstructured":"Na, R. et al. Iatrogenic immunosuppression and risk of non-Hodgkin lymphoma in solid organ transplantation: A population-based cohort study in Australia. Br. J. Haematol. 174(4), 550\u2013562 (2016).","journal-title":"Br. J. Haematol."},{"issue":"3","key":"50602_CR37","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1097\/TP.0000000000001201","volume":"101","author":"JA O\u2019Regan","year":"2017","unstructured":"O\u2019Regan, J. A. et al. Posttransplant lymphoproliferative disorders in Irish renal transplant recipients: Insights from a national observational study. Transplantation 101(3), 657\u2013663 (2017).","journal-title":"Transplantation"},{"issue":"11","key":"50602_CR38","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1093\/aje\/kws375","volume":"177","author":"B Pasternak","year":"2013","unstructured":"Pasternak, B. et al. Use of azathioprine and the risk of cancer in inflammatory bowel disease. Am. J. Epidemiol. 177(11), 1296\u20131305 (2013).","journal-title":"Am. J. Epidemiol."},{"issue":"3","key":"50602_CR39","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1111\/ene.12329","volume":"21","author":"EG Pedersen","year":"2014","unstructured":"Pedersen, E. G. et al. Risk of non-melanoma skin cancer in myasthenia patients treated with azathioprine. Eur. J. Neurol. 21(3), 454\u2013458 (2014).","journal-title":"Eur. J. Neurol."},{"issue":"2","key":"50602_CR40","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1111\/j.1440-1746.2011.06865.x","volume":"27","author":"M Setshedi","year":"2012","unstructured":"Setshedi, M. et al. Use of thiopurines in the treatment of inflammatory bowel disease is associated with an increased risk of non-melanoma skin cancer in an at-risk population: A cohort study. J. Gastroenterol. Hepatol. 27(2), 385\u2013389 (2012).","journal-title":"J. Gastroenterol. Hepatol."},{"issue":"5","key":"50602_CR41","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1053\/j.gastro.2011.07.039","volume":"141","author":"H Singh","year":"2011","unstructured":"Singh, H. et al. Increased risk of nonmelanoma skin cancers among individuals with inflammatory bowel disease. Gastroenterology 141(5), 1612\u20131620 (2011).","journal-title":"Gastroenterology"},{"issue":"9701","key":"50602_CR42","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.1016\/S0140-6736(09)61302-7","volume":"374","author":"L Beaugerie","year":"2009","unstructured":"Beaugerie, L. et al. Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: A prospective observational cohort study. Lancet 374(9701), 1617\u20131625 (2009).","journal-title":"Lancet"},{"issue":"4","key":"50602_CR43","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1001\/archinternmed.2007.107","volume":"168","author":"S Bernatsky","year":"2008","unstructured":"Bernatsky, S., Clarke, A. E. & Suissa, S. Hematologic malignant neoplasms after drug exposure in rheumatoid arthritis. Arch. Intern. Med. 168(4), 378\u2013381 (2008).","journal-title":"Arch. Intern. Med."},{"issue":"1","key":"50602_CR44","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1136\/ard.2006.069039","volume":"67","author":"S Bernatsky","year":"2008","unstructured":"Bernatsky, S. et al. The relationship between cancer and medication exposures in systemic lupus erythaematosus: A case-cohort study. Ann. Rheum. Dis. 67(1), 74\u201379 (2008).","journal-title":"Ann. Rheum. Dis."},{"issue":"5","key":"50602_CR45","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1053\/j.gastro.2013.07.035","volume":"145","author":"N Khan","year":"2013","unstructured":"Khan, N. et al. Risk of lymphoma in patients with ulcerative colitis treated with thiopurines: A nationwide retrospective cohort study. Gastroenterology 145(5), 1007-1015.e3 (2013).","journal-title":"Gastroenterology"},{"issue":"4","key":"50602_CR46","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1002\/ajh.23385","volume":"88","author":"SM Mbulaiteye","year":"2013","unstructured":"Mbulaiteye, S. M. et al. Burkitt lymphoma risk in U.S. solid organ transplant recipients. Am. J. Hematol. 88(4), 245\u2013250 (2013).","journal-title":"Am. J. Hematol."},{"issue":"3","key":"50602_CR47","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.ejim.2010.02.009","volume":"21","author":"T Zimmermann","year":"2010","unstructured":"Zimmermann, T. et al. Liver transplanted patients with preoperative autoimmune hepatitis and immunological disorders are at increased risk for Post-Transplant Lymphoproliferative Disease (PTLD). Eur. J. Intern. Med. 21(3), 208\u2013215 (2010).","journal-title":"Eur. J. Intern. Med."},{"issue":"1","key":"50602_CR48","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/ijc.2910630102","volume":"63","author":"JM Kaldor","year":"1995","unstructured":"Kaldor, J. M. et al. Bladder tumours following chemotherapy and radiotherapy for ovarian cancer: A case-control study. Int. J. Cancer 63(1), 1\u20136 (1995).","journal-title":"Int. J. Cancer"},{"issue":"7","key":"50602_CR49","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1093\/jnci\/87.7.524","volume":"87","author":"LB Travis","year":"1995","unstructured":"Travis, L. B. et al. Bladder and kidney cancer following cyclophosphamide therapy for non-Hodgkin\u2019s lymphoma. J. Natl. Cancer Inst. 87(7), 524\u2013530 (1995).","journal-title":"J. Natl. Cancer Inst."},{"issue":"7","key":"50602_CR50","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.3109\/10428194.2012.743657","volume":"54","author":"Y Xu","year":"2013","unstructured":"Xu, Y. et al. Risk of second malignant neoplasms after cyclophosphamide-based chemotherapy with or without radiotherapy for non-Hodgkin lymphoma. Leuk. Lymphoma 54(7), 1396\u20131404 (2013).","journal-title":"Leuk. Lymphoma"},{"issue":"26","key":"50602_CR51","doi-asserted-by":"publisher","first-page":"1745","DOI":"10.1056\/NEJM199206253262605","volume":"326","author":"RE Curtis","year":"1992","unstructured":"Curtis, R. E. et al. Risk of leukemia after chemotherapy and radiation treatment for breast cancer. N. Engl. J. Med. 326(26), 1745\u20131751 (1992).","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"50602_CR52","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1056\/NEJM199001043220101","volume":"322","author":"JM Kaldor","year":"1990","unstructured":"Kaldor, J. M. et al. Leukemia following chemotherapy for ovarian cancer. N. Engl. J. Med. 322(1), 1\u20136 (1990).","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"50602_CR53","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1038\/bjc.1991.174","volume":"63","author":"A Nandakumar","year":"1991","unstructured":"Nandakumar, A. et al. Myeloid leukaemia following therapy for a first primary cancer. Br. J. Cancer 63(5), 782\u2013788 (1991).","journal-title":"Br. J. Cancer"},{"issue":"19","key":"50602_CR54","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1093\/jnci\/86.19.1450","volume":"86","author":"LB Travis","year":"1994","unstructured":"Travis, L. B. et al. Risk of leukemia following treatment for non-Hodgkin\u2019s lymphoma. J. Natl. Cancer Inst. 86(19), 1450\u20131457 (1994).","journal-title":"J. Natl. Cancer Inst."},{"issue":"3","key":"50602_CR55","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1046\/j.1365-2141.2000.02188.x","volume":"110","author":"G Finazzi","year":"2000","unstructured":"Finazzi, G. et al. Second malignancies in patients with essential thrombocythaemia treated with busulphan and hydroxyurea: Long-term follow-up of a randomized clinical trial. Br. J. Haematol. 110(3), 577\u2013583 (2000).","journal-title":"Br. J. Haematol."},{"issue":"7","key":"50602_CR56","doi-asserted-by":"publisher","first-page":"2664","DOI":"10.1182\/blood-2004-09-3426","volume":"105","author":"G Finazzi","year":"2005","unstructured":"Finazzi, G. et al. Acute leukemia in polycythemia vera: An analysis of 1638 patients enrolled in a prospective observational study. Blood 105(7), 2664\u20132670 (2005).","journal-title":"Blood"},{"issue":"3","key":"50602_CR57","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1046\/j.1523-1747.2000.00898.x","volume":"114","author":"A Hannuksela-Svahn","year":"2000","unstructured":"Hannuksela-Svahn, A. et al. Psoriasis, its treatment, and cancer in a cohort of Finnish patients. J. Invest. Dermatol. 114(3), 587\u2013590 (2000).","journal-title":"J. Invest. Dermatol."},{"issue":"5","key":"50602_CR58","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1056\/NEJM199902043400504","volume":"340","author":"LB Travis","year":"1999","unstructured":"Travis, L. B. et al. Risk of leukemia after platinum-based chemotherapy for ovarian cancer. N. Engl. J. Med. 340(5), 351\u2013357 (1999).","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"50602_CR59","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1093\/jnci\/94.3.182","volume":"94","author":"LB Travis","year":"2002","unstructured":"Travis, L. B. et al. Lung cancer following chemotherapy and radiotherapy for Hodgkin\u2019s disease. J. Natl. Cancer Inst. 94(3), 182\u2013192 (2002).","journal-title":"J. Natl. Cancer Inst."},{"issue":"6","key":"50602_CR60","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1200\/JCO.2003.04.100","volume":"21","author":"MC Le Deley","year":"2003","unstructured":"Le Deley, M. C. et al. Risk of secondary leukemia after a solid tumor in childhood according to the dose of epipodophyllotoxins and anthracyclines: A case-control study by the Soci\u00e9t\u00e9 Fran\u00e7aise d\u2019Oncologie P\u00e9diatrique. J. Clin. Oncol. 21(6), 1074\u20131081 (2003).","journal-title":"J. Clin. Oncol."},{"issue":"17","key":"50602_CR61","doi-asserted-by":"publisher","first-page":"3140","DOI":"10.1182\/blood-2010-05-280883","volume":"116","author":"M Crowther","year":"2010","unstructured":"Crowther, M., Lim, W. & Crowther, M. A. Systematic review and meta-analysis methodology. Blood 116(17), 3140\u20133146 (2010).","journal-title":"Blood"},{"issue":"4","key":"50602_CR62","first-page":"219","volume":"5","author":"T Greco","year":"2013","unstructured":"Greco, T. et al. Meta-analysis: Pitfalls and hints. Heart Lung Vessel 5(4), 219\u2013225 (2013).","journal-title":"Heart Lung Vessel"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-50602-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-50602-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-50602-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,3]],"date-time":"2024-01-03T18:06:28Z","timestamp":1704305188000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-50602-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,3]]},"references-count":62,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["50602"],"URL":"https:\/\/doi.org\/10.1038\/s41598-023-50602-6","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,3]]},"assertion":[{"value":"15 May 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 December 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 January 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"413"}}